Physician profile
Anthony P Benjamin
NPI 1932165628
$3,458.05
in general payments reported to CMS, 2019-2025
24 companies · $514 in 2025
The $514 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $290 · 2021: $413 · 2022: $189 · 2023: $719 · 2024: $800 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,934 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,933.58 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $579.62 | 2019-2025 | Xtandi |
| Teleflex LLC | $484.10 | 2021-2025 | Urolift |
| Janssen Biotech, INC. | $388.82 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Procept Biorobotics Corporation | $343.32 | 2023 | Aquabeam Robotic System |
| Pfizer INC. | $262.82 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $225.10 | 2021-2024 | Myrisk |
| Boston Scientific Corporation | $178.27 | 2019-2024 | Lumenis Pulse 120h |
| Sumitomo Pharma America, INC. | $177.81 | 2023-2025 | Gemtesa |
| Urogen Pharma, INC. | $134.62 | 2022-2024 | Jelmyto |
| Axonics, INC. | $103.99 | 2020-2024 | Axonics |
| Antares Pharma, INC. | $98.88 | 2021-2023 | Tlando, Nocdurna, Xyosted |
| Abbvie INC. | $84.39 | 2020-2025 | Lupron Depot |
| Hollister Incorporated | $60.21 | 2021-2022 | |
| Allergan, INC. | $59.68 | 2021 | |
| Novartis Pharmaceuticals Corporation | $55.99 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $52.73 | 2019-2023 | Speedicath |
| Smith+Nephew, INC. | $31.49 | 2019 | |
| Endo Pharmaceuticals INC. | $26.42 | 2019 | |
| Lemaitre Vascular, INC. | $24.21 | 2024 | Hydro Lemaitre Valvulotome |
| Olympus America INC. | $20.64 | 2024 | Itind System |
| Laborie Medical Technologies Corp. | $20.32 | 2023 | |
| Myovant Sciences INC. | $18.61 | 2021 | |
| Mission Pharmacal Company | $14.18 | 2022 | |
| Melinta Therapeutics, LLC | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.